Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8794977 | 0.85 | CA12 (0.44) | ALDH1A1MAPTGAANPC1RAB9A | |
| SCHEMBL2577919 | 0.85 | ALDH1A1 (0.59) | ALDH1A1MAPTGAANPC1RAB9A | |
| SCHEMBL13074497 | 0.83 | APP (0.43) | ALDH1A1MAPTGAANPC1RAB9A | |
| Hydrochloric Acid SCHEMBL27993084 | 0.83 | ALDH1A1 (0.57) | ALDH1A1MAPTGAANPC1RAB9A | |
| SCHEMBL28809274 | 0.82 | ALDH1A1 (0.42) | ALDH1A1MAPTGAANPC1RAB9A | |
| Hydrochloric Acid SCHEMBL8683952 | 0.80 | ALDH1A1 (0.42) | ALDH1A1MAPTGAANPC1RAB9A | |
| SCHEMBL1501174 | 0.79 | CA1 (0.58) | ALDH1A1MAPTCA12CA1CA2 | |
| SCHEMBL8139679 | 0.79 | ALDH1A1 (0.44) | ALDH1A1MAPTGAANPC1RAB9A | |
| SCHEMBL12885789 | 0.79 | ALDH1A1 (0.44) | ALDH1A1MAPTGAANPC1RAB9A | |
| Ammonia Solution, Strong SCHEMBL2233000 | 0.77 | CA1 (0.55) | ALDH1A1MAPTCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633320-B2 | Process for preparing bromo-substituted quinolines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-21 | — | — | US | disclosed |
| US-20120165534-A1 | PROCESS FOR PREPARING BROMO-SUBSTITUTED QUINOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | US | disclosed |
| US-7884246-B2 | starting from substituted cyclic hydroxy-ketones via aromatization through a substituted oxime intermediate; avoids the use of cryogenic conditions, minimizes the number of operations for an overall faster cycle time; in the preperation of drugs for hepatitis C viral infections | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-08 | — | — | US | disclosed |
| US-20080293972-A1 | Process for Preparing Substituted Anisidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165534-A1 | PROCESS FOR PREPARING BROMO-SUBSTITUTED QUINOLINES | HCCS, CYP3A7, ABL1 | ALDH1A1 385/4885MAPT 4445/4885GAA 442/4885 |
| US-20080293972-A1 | Process for Preparing Substituted Anisidines | ALKBH3, ALKBH1, ALK | ALDH1A1 163/4885MAPT 4669/4885GAA 1661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.